A group of molecules found in many trendy anti-aging treatments may actually feed cells in already existing cancers, a study from researchers at Tokyo University of Science has revealed.
Funding supports IND-enabling activities for Casma’s CSM-101, a first-in-class TRPML1 agonist targeting lysosomal dysfunction in genetically driven neurodegenerative diseasesCAMBRIDGE, ...
Pancreatic cancer cells can regulate their tolerance to chemotherapy depending on what they detect in their surroundings, according to NYU Langone researchers. With that, it’s unlikely that a single ...
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet-fed female mice Treatment preserved hepatic ...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs, today announced new female-specific ...
MindImmune today announced a transformative $5 million award from the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate development of its lead therapeutic candidate, MITI-101 ? a ...
Eating Protein Saves Lives, Inc. a leader in nutritional approaches to addiction treatment and recovery, announces the launch ...
Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors ...
Alcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and liver-related mortality worldwide, with few effective therapies.
Protein aggregates as hallmarks of severe alcohol-related liver injuryAlcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and ...
News-Medical.Net on MSN
A review of methionine dependency in modern cancer therapy
Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear ...
A recent review identifies interleukin-36 (IL-36) as a transformative driver of vascular inflammation, revealing that serum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results